ReviewImmunotherapy2010
Directing dendritic cell immunotherapy towards successful cancer treatment.
Review in Immunotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of Using Dendritic Cells in the Treatment of Prostate Cancer: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Myeloid-derived suppressor cells in the patients with liver resection for hepatitis B virus-related hepatocellular carcinoma.Scientific reports · 2019Trial
- Tumor Lysate-Stimulated Dendritic Cell Production: A Cross-Sectional Study.Journal of clinical practice and research · 2026Article
- Review
- Innate immune signaling-driven myeloid remodeling in cancer: inflammatory amplification, immune suppression, and therapeutic targeting.Frontiers in immunology · 2026Review
- Iron Oxide Magnetic Nanoparticles Synthesized by Laser Target Evaporation Method for the Needs of Cancer Immunotherapy.Materials (Basel, Switzerland) · 2025Article
- Review
- Review
- Immune Modulation Strategies in Gene Therapy: Overcoming Immune Barriers and Enhancing Efficacy.Current gene therapy · 2025Review
- Cancer vaccines: an update on recent achievements and prospects for cancer therapy.Clinical and experimental medicine · 2024Review
- Tug of war: Understanding the dynamic interplay of tumor biomechanical environment on dendritic cell function.Mechanobiology in medicine · 2024Review
- Review
- Checkpoint inhibitor-expressing lentiviral vaccine suppresses tumor growth in preclinical cancer models.Journal for immunotherapy of cancer · 2024Article
- Article
- Dendritic Cell-Based Immunotherapy: The Importance of Dendritic Cell Migration.Journal of immunology research · 2024Review
- Review
- Precision-engineering of subunit vaccine particles for prevention of infectious diseases.Frontiers in immunology · 2023Review
- TLR9 and Glioma: Friends or Foes?Cells · 2022Review
- Chemical and Synthetic Biology Approaches for Cancer Vaccine Development.Molecules (Basel, Switzerland) · 2022Review
- Exosomal Communication Between the Tumor Microenvironment and Innate Immunity and Its Therapeutic Application.Immune network · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The use of dendritic cells (DCs) for tumor immunotherapy represents a powerful approach for harnessing the patient's own immune system to eliminate tumor cells. However, suboptimal conditions for generating potent immunostimulatory DCs, as well as the induction of tolerance and suppression mediated by the tumors and its microenvironment have contributed to limited success. Combining DC vaccines with new approaches that enhance immunogenicity and overcome the regulatory mechanisms underlying peripheral tolerance may be the key to achieving effective and durable anti-tumor immune responses that translate to better clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.